The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $170.85

Today's change-1.34 -0.78%
Updated September 1 4:15 PM EDT. Delayed by at least 15 minutes.
 

Alexion Pharmaceuticals Inc

Nasdaq: ALXN
Last

(U.S.) $170.85

Today's change-1.34 -0.78%
Updated September 1 4:15 PM EDT. Delayed by at least 15 minutes.

Alexion Pharmaceuticals Inc down (U.S.)$1.34

Alexion Pharmaceuticals Inc closed lower Tuesday, dropping (U.S.)$1.34 or 0.78% to (U.S.)$170.85. Over the last five days, shares have gained 3.27%, but are down 7.66% for the last year to date. Shares have outperformed the S&P 500 by 5.39% during the last year.

Key company metrics

  • Open(U.S.) $168.62
  • Previous close(U.S.) $172.19
  • High(U.S.) $174.78
  • Low(U.S.) $168.08
  • Bid / Ask(U.S.) $166.02 / (U.S.) $186.71
  • YTD % change-7.66%
  • Volume2,551,121
  • Average volume (10-day)1,999,508
  • Average volume (1-month)1,500,916
  • Average volume (3-month)1,829,545
  • 52-week range(U.S.) $150.06 to (U.S.) $208.88
  • Beta0.73
  • Trailing P/E58.38×
  • P/E 1 year forward35.55×
  • Forward PEG2.11×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $2.93
Updated September 1 4:15 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+24.78%

Based on its net profit margin of 24.78%, Alexion Pharmaceuticals Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.72%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue636600599555
Total other revenue--------
Total revenue636600599555
Gross profit584531550503
Total cost of revenue52694952
Total operating expense455497396318
Selling / general / administrative221187184158
Research & development12621612597
Depreciation / amortization6543
Interest expense (income), net operating--------
Unusual expense (income)5019338
Other operating expenses, total--------
Operating income181104204237
Interest income (expense), net non-operating---1-1--
Gain (loss) on sale of assets--------
Other--------
Income before tax177107205236
Income after tax17091153178
Income tax, total7165258
Net income17091153178
Total adjustments to net income--------
Net income before extra. items17091153178
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items17091153178
Inc. avail. to common incl. extra. items17091153178
Diluted net income17091153178
Dilution adjustment------0
Diluted weighted average shares205202202201
Diluted EPS excluding extraordinary itemsvalue per share0.830.450.760.88
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.070.530.880.91